Soleno Therapeutics, Inc. (SLNO)
53.01
0.00 (0.00%)
USD |
NASDAQ |
May 18, 16:00
Soleno Therapeutics Research and Development Expense (Quarterly) : 11.27M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Neurocrine Biosciences, Inc. | 296.20M |
| Nektar Therapeutics | 35.68M |
| XOMA Royalty Corp. | 0.049M |
| Apellis Pharmaceuticals, Inc. | 76.96M |
| Forian, Inc. | 0.9615M |